A Randomized, Placebo-controlled, Prospective, Double-blind, Multicenter Phase 2/3 Study of the Efficacy and Safety of SANGUINATE™ for Reduction of Delayed Graft Function in Recipients of a Donation After Brain Death Kidney Transplant.

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 02 Nov 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PEG-haemoglobin carbon monoxide (Primary)
Indications Delayed graft function
Focus Adverse reactions; Therapeutic Use
Sponsors Prolong Pharmaceuticals

Most Recent Events

26 Oct 2016 Status changed from recruiting to completed.
14 Jun 2016 Planned End Date changed from 1 May 2016 to 1 Jun 2016.
14 Jun 2016 Planned primary completion date changed from 1 May 2016 to 1 Jun 2016.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight